859TiPTALAPRO-1: An open-label, response rate phase II study of talazoparib (TALA) in men with DNA damage repair defects (DDR) and metastatic castration-resistant prostate cancer (mCRPC) who previously received taxane-based chemotherapy (CT) and progressed on ≥ 1 novel hormonal therapy (NHT). (23rd October 2018)

Record Type:: Journal Article
Title:: 859TiPTALAPRO-1: An open-label, response rate phase II study of talazoparib (TALA) in men with DNA damage repair defects (DDR) and metastatic castration-resistant prostate cancer (mCRPC) who previously received taxane-based chemotherapy (CT) and progressed on ≥ 1 novel hormonal therapy (NHT). (23rd October 2018)
Main Title:: 859TiPTALAPRO-1: An open-label, response rate phase II study of talazoparib (TALA) in men with DNA damage repair defects (DDR) and metastatic castration-resistant prostate cancer (mCRPC) who previously received taxane-based chemotherapy (CT) and progressed on ≥ 1 novel hormonal therapy (NHT)
Authors:: de Bono, J S
Higano, C
Saad, F
Miller, K
Casey, M
Czibere, A
Healy, C
Fizazi, K
Abstract:
Is Part Of:: Annals of oncology. Volume 29(2018)Supplement 8
Journal:: Annals of oncology
Issue:: Volume 29(2018)Supplement 8
Issue Display:: Volume 29, Issue 8 (2018)
Year:: 2018
Volume:: 29
Issue:: 8
Issue Sort Value:: 2018-0029-0008-0000
Page Start:
Page End:
Publication Date:: 2018-10-23
Subjects:: Oncology -- Periodicals
616.992
Journal URLs:: https://www.journals.elsevier.com/annals-of-oncology ↗
http://ukcatalogue.oup.com/ ↗
DOI:: 10.1093/annonc/mdy284.068 ↗
Languages:: English
ISSNs:: 0923-7534
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - 1043.320000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:: 12254.xml